NXTC

NextCure, Inc.

Price Chart

Latest Quote

$1.83

+0.08 (+4.57%)

Current Price

Previous Close	$1.75
Open	$1.70
Day High	$1.85
Day Low	$1.65
Volume	66,968

Fetched: 2026-06-23T17:33:56

Stock Information

Shares Outstanding	3.61M
Total Debt	$4.91M
Cash Equivalents	$29.74M
Net Income	$-54.66M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$6.61M
EPS (TTM)	$-16.82
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-18.51M
Income	$-54.66M
Book/sh	$7.41
Cash/sh	$8.23
Employees	40

Financial Ratios

Quick Ratio	4.42
Current Ratio	4.61
Debt/Eq	18.39

Returns & Margins

ROA	-66.71%
ROE	-132.41%

Ownership

Insider Ownership	14.80%
Institutional Ownership	62.54%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.22
P/B	0.25

Analyst Data

Recommendation	strong_buy
Target Price	$19.33

Technical Indicators

SMA20	$3.26
SMA50	$7.45
SMA200	$9.79
RSI	15.72
ATR	0.3606

Shares Float	2.26M
Short Float	1.90%
Short Ratio	1.70
Volatility	1.30
Rel Volume	0.40

Performance History

Week	-7.58%
Month	-82.06%
Quarter	-82.42%
6 Months	-82.90%
YTD	-86.22%
Year	-67.55%
3 Years	-90.87%
5 Years	-98.13%
10 Years	-99.23%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$1.83	66,968
2026-06-22	$1.75	175,000
2026-06-18	$2.02	59,400
2026-06-17	$2.20	184,800
2026-06-16	$1.96	192,700
2026-06-15	$1.98	140,100
2026-06-12	$2.08	214,900
2026-06-11	$2.23	136,200
2026-06-10	$2.23	131,000
2026-06-09	$2.33	141,700
2026-06-08	$2.79	160,100
2026-06-05	$2.95	106,900
2026-06-04	$3.19	79,600
2026-06-03	$3.15	141,200
2026-06-02	$3.40	248,100
2026-06-01	$3.38	922,500
2026-05-29	$6.20	11,500
2026-05-28	$6.40	31,600
2026-05-27	$6.07	97,000
2026-05-26	$7.02	86,800

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

📰 Latest News

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?

Zacks • 2025-11-11T14:55:02Z

Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky

Simply Wall St. • 2025-10-18T12:10:41Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$57,616,000	$57,206,000	$67,637,000	$75,909,000
Other Income Expense	$1,772,000	$1,552,000	$4,914,000	$1,176,000
Other Non Operating Income Expenses	$1,772,000	$4,094,000	$4,914,000	$1,176,000
Operating Expense	$57,616,000	$57,206,000	$67,637,000	$75,909,000
General And Administrative Expense	$12,693,000	$15,718,000	$19,706,000	$21,710,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Normalized Income	$-55,844,000	$-53,112,000	$-62,723,000	$-74,733,000
Net Income From Continuing And Discontinued Operation	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Total Operating Income As Reported	$-57,616,000	$-59,748,000	$-67,637,000	$-75,909,000
Net Income Common Stockholders	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Net Income	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Net Income Including Noncontrolling Interests	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Net Income Continuous Operations	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Pretax Income	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Special Income Charges	$0	$-2,542,000	$0	-
Operating Income	$-57,616,000	$-57,206,000	$-67,637,000	$-75,909,000
Per Share
Diluted EPS	$-19.65	$-23.88	$-27.00	$-32.28
Basic EPS	$-19.65	$-23.88	$-27.00	$-32.28
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-55,431,000	$-51,799,000	$-63,953,000	$-71,785,000
Total Unusual Items	$0	$-2,542,000	$0	-
Total Unusual Items Excluding Goodwill	$0	$-2,542,000	$0	-
Reconciled Depreciation	$2,185,000	$2,865,000	$3,684,000	$4,124,000
EBITDA (Bullshit earnings)	$-55,431,000	$-54,341,000	$-63,953,000	$-71,785,000
EBIT	$-57,616,000	$-57,206,000	$-67,637,000	$-75,909,000
Diluted Average Shares	$2,842,448	$2,330,386	$2,319,715	$2,312,017
Basic Average Shares	$2,842,448	$2,330,386	$2,319,715	$2,312,017
Diluted NI Availto Com Stockholders	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Restructuring And Mergern Acquisition	$0	$2,542,000	$0	-
Research And Development	$44,923,000	$41,488,000	$47,931,000	$54,199,000
Selling General And Administration	$12,693,000	$15,718,000	$19,706,000	$21,710,000
Other Gand A	$12,693,000	$15,718,000	$19,706,000	$21,710,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Total Assets	$50,183,000	$80,860,000	$128,038,000	$184,161,000
Total Non Current Assets	$6,436,000	$9,053,000	$15,313,000	$20,178,000
Other Non Current Assets	$546,000	$332,000	$1,882,000	$3,265,000
Current Assets	$43,747,000	$71,807,000	$112,725,000	$163,983,000
Other Current Assets	$1,929,000	$3,186,000	$4,426,000	$4,072,000
Cash Cash Equivalents And Short Term Investments	$41,818,000	$68,621,000	$108,299,000	$159,911,000
Cash And Cash Equivalents	$25,982,000	$27,727,000	$13,082,000	$26,630,000
Restricted Cash	-	-	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$5,153,000	$5,949,000	$6,605,000	$7,123,000
Long Term Debt And Capital Lease Obligation	$4,148,000	$5,153,000	$5,949,000	$6,605,000
Current Debt And Capital Lease Obligation	$1,005,000	$796,000	$656,000	$518,000
Liabilities
Total Liabilities Net Minority Interest	$15,240,000	$15,388,000	$13,617,000	$16,631,000
Total Non Current Liabilities Net Minority Interest	$4,674,000	$5,814,000	$6,734,000	$7,504,000
Other Non Current Liabilities	$526,000	$661,000	$785,000	$899,000
Current Liabilities	$10,566,000	$9,574,000	$6,883,000	$9,127,000
Other Current Liabilities	$135,000	$124,000	$113,000	$105,000
Payables And Accrued Expenses	$9,426,000	$8,654,000	$6,114,000	$8,504,000
Payables	$2,011,000	$5,353,000	$2,330,000	$4,270,000
Accounts Payable	$2,011,000	$5,353,000	$2,330,000	$4,270,000
Non Current Deferred Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Total Equity Gross Minority Interest	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Stockholders Equity	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Gains Losses Not Affecting Retained Earnings	$21,000	$4,000	$-222,000	$-1,494,000
Other Equity Adjustments	$21,000	$4,000	$-222,000	$-1,494,000
Retained Earnings	$-435,980,000	$-380,136,000	$-324,482,000	$-261,759,000
Other
Ordinary Shares Number	$3,505,621	$2,333,890	$2,325,252	$2,314,544
Share Issued	$3,505,621	$2,333,890	$2,325,252	$2,314,544
Tangible Book Value	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Invested Capital	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Working Capital	$33,181,000	$62,233,000	$105,842,000	$154,856,000
Capital Lease Obligations	$5,153,000	$5,949,000	$6,605,000	$7,123,000
Total Capitalization	$34,943,000	$65,472,000	$114,421,000	$167,530,000
Additional Paid In Capital	$470,898,000	$445,602,000	$439,097,000	$430,755,000
Capital Stock	$4,000	$2,000	$28,000	$28,000
Common Stock	$4,000	$2,000	$28,000	$28,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$4,148,000	$5,153,000	$5,949,000	$6,605,000
Current Capital Lease Obligation	$1,005,000	$796,000	$656,000	$518,000
Current Accrued Expenses	$7,415,000	$3,301,000	$3,784,000	$4,234,000
Net PPE	$5,890,000	$8,721,000	$13,431,000	$16,913,000
Accumulated Depreciation	$-25,280,000	$-23,095,000	$-20,229,000	$-16,630,000
Gross PPE	$31,170,000	$31,816,000	$33,660,000	$33,543,000
Leases	$9,309,000	$9,309,000	$9,309,000	$9,336,000
Other Properties	$20,767,000	$21,413,000	$23,032,000	$22,260,000
Machinery Furniture Equipment	$1,094,000	$1,094,000	$1,094,000	$1,094,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$15,836,000	$40,894,000	$95,217,000	$133,281,000
Construction In Progress	-	$0	$225,000	$853,000

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-49,613,000	$-41,279,000	$-53,794,000	$-56,002,000
Operating Activities
Operating Cash Flow	$-49,613,000	$-40,805,000	$-52,974,000	$-53,886,000
Cash Flow From Continuing Operating Activities	$-49,613,000	$-40,805,000	$-52,974,000	$-53,886,000
Operating Gains Losses	-	-	-	$87,000
Investing Activities
Investing Cash Flow	$25,556,000	$55,306,000	$39,272,000	$67,979,000
Cash Flow From Continuing Investing Activities	$25,556,000	$55,306,000	$39,272,000	$67,979,000
Capital Expenditure	-	$-474,000	$-820,000	$-2,116,000
Financing Activities
Issuance Of Capital Stock	$22,276,000	$39,000	$5,000	-
Financing Cash Flow	$22,312,000	$144,000	$154,000	$200,000
Cash Flow From Continuing Financing Activities	$22,312,000	$144,000	$154,000	$200,000
Net Common Stock Issuance	$22,276,000	$39,000	$5,000	-
Common Stock Issuance	$22,276,000	$39,000	$5,000	-
Other
Interest Paid Supplemental Data	$62,000	$72,000	$81,000	$90,000
End Cash Position	$25,982,000	$27,727,000	$13,082,000	$26,630,000
Beginning Cash Position	$27,727,000	$13,082,000	$26,630,000	$12,337,000
Changes In Cash	$-1,745,000	$14,645,000	$-13,548,000	$14,293,000
Proceeds From Stock Option Exercised	$36,000	$105,000	$149,000	$200,000
Net Investment Purchase And Sale	$25,556,000	$55,780,000	$40,092,000	$70,095,000
Sale Of Investment	$52,261,000	$104,228,000	$113,597,000	$104,739,000
Purchase Of Investment	$-26,705,000	$-48,448,000	$-73,505,000	$-34,644,000
Net PPE Purchase And Sale	$0	$-474,000	$-820,000	$-2,116,000
Purchase Of PPE	$0	$-474,000	$-820,000	$-2,116,000
Change In Working Capital	$954,000	$4,532,000	$-1,940,000	$3,725,000
Change In Other Current Liabilities	$-1,140,000	$-920,000	$-770,000	$0
Change In Payables And Accrued Expense	$992,000	$2,691,000	$-2,244,000	$1,687,000
Change In Accrued Expense	$4,334,000	$-332,000	$-304,000	$-641,000
Change In Payable	$-3,342,000	$3,023,000	$-1,940,000	$2,328,000
Change In Account Payable	$-3,342,000	$3,023,000	$-1,940,000	$2,328,000
Change In Prepaid Assets	$1,102,000	$2,761,000	$1,074,000	$2,038,000
Other Non Cash Items	$587,000	$561,000	$573,000	$356,000
Stock Based Compensation	$2,986,000	$6,335,000	$8,188,000	$9,508,000
Asset Impairment Charge	$0	$1,786,000	$0	-
Amortization Of Securities	$-481,000	$-1,230,000	$-756,000	$3,047,000
Depreciation Amortization Depletion	$2,185,000	$2,865,000	$3,684,000	$4,124,000
Depreciation And Amortization	$2,185,000	$2,865,000	$3,684,000	$4,124,000
Net Income From Continuing Operations	$-55,844,000	$-55,654,000	$-62,723,000	$-74,733,000
Gain Loss On Sale Of PPE	-	-	$0	$87,000
Repayment Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Income Tax Paid Supplemental Data	-	-	-	-
Change In Other Working Capital	-	-	-	-

Fetched: 2026-06-16